Used as a carbonic anhydrase inhibitor designed for medical applications, particularly in the treatment of glaucoma, as it helps reduce intraocular pressure. The mechanism of action involves inhibiting carbonic anhydrase type II and other isoforms, which play a key role in the production of aqueous humor within the eye.

Additionally, this compound shows potential for treating conditions associated with excessive acid production, such as certain neurological disorders or specific cancers, due to the enzyme's involvement in regulating acid-base balance in the body.

In pharmaceutical research, it has been developed to enhance water solubility and prolong the duration of action, making it suitable for formulations like eye drops or long-acting oral tablets. The goal is to minimize side effects and improve therapeutic efficacy compared to traditional carbonic anhydrase inhibitors.